NCT07169695 - A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

March 2, 2026

Primary Completion Date

January 21, 2027

Study Completion Date

January 21, 2027

Conditions

Moderate to Severe Vernal Keratoconjunctivitis

Interventions

DIAGNOSTIC_TEST

Slit Lamp Examination

The participant will have a slit lamp examination

DIAGNOSTIC_TEST

Far Best Corrected Visual Acuity (BCVA)

The participant 's BCVA will be evaluated.

DRUG

T1695

The participant should instill T1695.

DRUG

Ciclosporin

The participant should instill Ciclosporin.

DIAGNOSTIC_TEST

Corneal fluorescein staining score on modified Oxford scale

One drop of fluorescein will be instilled to assess the fluorescein staining score on the modified Oxford scale.